Catalyst Pharmaceuticals has been an important part of Florida’s life sciences sector for almost 25 years.
At a recent BioFlorida event, President and CEO Rich Daly detailed what’s ahead for the industry in a keynote speech and panel discussion. “We have seen our area transition from an emerging market to a scaled and increasingly coordinated ecosystem. Florida’s life sciences ecosystem is no longer defined by its potential, but by its trajectory.”
The state is now home to more than 9,400 life sciences companies employing more than 116,000 professionals, generating more than $64 billion in economic output. Florida ranks among the top states nationally in medical device manufacturing, biotechnology R&D, and clinical trial activity, supported by a strong academic infrastructure and approximately $1.5 billion in annual university research investment. At the same time, a population of nearly 23 million, combined with an aging demographic profile, is driving sustained demand for healthcare innovation.
What makes this moment different is the convergence of forces accelerating the ecosystem forward, mainly capital, talent, and institutional alignment.
Significant investment continues to flow into the state, including billions in bioscience venture capital and increasing participation from institutional investors with long-term perspectives on healthcare innovation. Companies across the pharmaceutical, biotechnology, medical technology, and diagnostics sectors are establishing meaningful operations in Florida, including headquarters and long-term development programs.
In parallel, the ecosystem itself is becoming more structured. Organizations like BioFlorida and the Miami Biotech Collective, along with integrated models like Lake Nona, are creating the structure and connectivity across industry, academia, and healthcare systems that define mature life sciences hubs.
Florida also brings unique structural advantages: a diverse population that expands access to clinical research, strong economic growth across major metros, and global connectivity that supports the movement of therapies and innovation.
This growth is closely tied to underlying healthcare needs. An estimated 2 million Floridians are living with a rare disease, and population growth in many regions is outpacing care capacity. The need for innovation, access, and faster diagnosis is real and immediate.
For companies like Catalyst, this reinforces a clear mission: to be part of the solution, not just the ecosystem. In addition to Catalyst’s corporate partnership with the Florida Society of Clinical Oncology (FLASCO), aimed at providing education, timely dissemination of pertinent information, and general support to Florida oncology healthcare professionals, the company recently made a $50,000 donation to Branches, a local Miami nonprofit. The donation will make a difference in advancing Branches’ mission to partner with families to build educational and financial assets, community, and hope. This investment helps provide life-changing opportunities for more than 550 students through afterschool tutoring, enrichment, college and career preparation, and post-secondary scholarships, while also reaching over 15,000 individuals through financial wellness services including coaching, free tax preparation, small business support, and emergency assistance.